Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials
Crossref DOI link: https://doi.org/10.1007/s13555-017-0181-6
Published Online: 2017-05-13
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Simpson, Eric L.
Funding for this research was provided by:
Sanofi (NA)
Regeneron Pharmaceuticals (NA)